Ser576
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser576  -  ZNF609 (human)

Site Information
VRLVEPHsPsPssKF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 453821
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 )
Disease tissue studied:
breast cancer ( 4 , 9 , 10 , 27 ) , breast ductal carcinoma ( 9 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 9 ) , cervical cancer ( 41 ) , cervical adenocarcinoma ( 41 ) , leukemia ( 30 , 50 , 51 , 52 ) , acute myelogenous leukemia ( 30 ) , chronic myelogenous leukemia ( 50 , 51 , 52 ) , lung cancer ( 7 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 27 ) , non-small cell lung cancer ( 14 , 15 , 17 , 18 , 19 , 24 , 27 ) , non-small cell lung adenocarcinoma ( 7 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , non-small cell large cell lung carcinoma ( 14 , 17 ) , non-small cell squamous cell lung carcinoma ( 16 ) , small-cell lung cancer ( 12 , 13 ) , neuroblastoma ( 26 ) , ovarian cancer ( 9 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 44 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 38 ) , 293 (epithelial) [AT1 (human), transfection] ( 35 ) , 786-O (renal) ( 5 ) , 786-O (renal) [VHL (human), transfection] ( 5 ) , A498 (renal) ( 40 ) , A549 (pulmonary) ( 21 ) , breast ( 2 , 9 ) , BT-20 (breast cell) ( 27 ) , BT-474 (breast cell) ( 4 ) , BT-549 (breast cell) ( 27 ) , Cal-12T (pulmonary) ( 19 ) , Calu 6 (pulmonary) ( 27 ) , Calu-3 (pulmonary) ( 15 ) , DMS153 (pulmonary) ( 18 ) , DMS53 (pulmonary) ( 13 ) , DMS79 (pulmonary) ( 12 ) , Flp-In T-Rex-293 (epithelial) ( 28 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 28 ) , GM00130 (B lymphocyte) ( 39 ) , GP293 (fibroblast) [NPM-ALK (human), transfection] ( 36 ) , H2009 (pulmonary) ( 27 ) , H2077 (pulmonary) ( 27 ) , H2887 (pulmonary) ( 27 ) , H322 (pulmonary) ( 27 ) , H322M (pulmonary) ( 27 ) , HCC1359 (pulmonary) ( 27 ) , HCC15 (pulmonary) ( 16 ) , HCC1937 (breast cell) ( 27 ) , HCC2279 (pulmonary) ( 27 ) , HCC366 (pulmonary) ( 27 ) , HCC4006 (pulmonary) ( 27 ) , HCC44 (pulmonary) ( 19 ) , HCC78 (pulmonary) ( 17 , 27 ) , HCC827 (pulmonary) ( 15 , 27 ) , HeLa (cervical) ( 1 , 8 , 25 , 34 , 42 , 46 , 48 , 53 , 55 , 56 ) , HeLa S3 (cervical) ( 41 ) , HMLER ('stem, breast cancer') ( 10 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 10 ) , HOP62 (pulmonary) ( 27 ) , HUES-7 ('stem, embryonic') ( 43 ) , HUES-9 ('stem, embryonic') ( 33 ) , Jurkat (T lymphocyte) ( 22 , 31 , 32 , 37 , 47 , 54 ) , K562 (erythroid) ( 25 , 42 , 49 , 50 , 51 , 52 ) , KG-1 (myeloid) ( 30 ) , LCLC-103H (pulmonary) ( 27 ) , liver ( 11 ) , LOU-NH91 (squamous) ( 16 , 27 ) , lung ( 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , MCF-7 (breast cell) ( 4 , 27 ) , MDA-MB-231 (breast cell) ( 27 ) , MDA-MB-468 (breast cell) ( 27 ) , NB10 (neural crest) ( 26 ) , NCI-H128 (pulmonary) ( 12 ) , NCI-H1299 (pulmonary) ( 14 ) , NCI-H1395 (pulmonary) ( 27 ) , NCI-H1417 (pulmonary) ( 12 ) , NCI-H1437 (pulmonary) ( 18 , 19 ) , NCI-H1568 (pulmonary) ( 27 ) , NCI-H157 (pulmonary) ( 27 ) , NCI-H1648 (pulmonary) ( 27 ) , NCI-H1650 (pulmonary) ( 15 ) , NCI-H1666 (pulmonary) ( 19 , 27 ) , NCI-H1703 (squamous) ( 16 ) , NCI-H1734 (pulmonary) ( 14 ) , NCI-H1781 (pulmonary) ( 17 ) , NCI-H1944 (pulmonary) ( 14 ) , NCI-H1975 (pulmonary) ( 15 ) , NCI-H2030 (pulmonary) ( 27 ) , NCI-H2073 (pulmonary) ( 16 , 18 ) , NCI-H209 (pulmonary) ( 12 , 18 ) , NCI-H2106 (pulmonary) ( 15 ) , NCI-H2172 (pulmonary) ( 27 ) , NCI-H2228 (pulmonary) ( 17 ) , NCI-H2342 (pulmonary) ( 16 ) , NCI-H2405 (pulmonary) ( 19 ) , NCI-H3122 (pulmonary) ( 17 , 24 ) , NCI-H358 (pulmonary) ( 14 ) , NCI-H446 (pulmonary) ( 13 ) , NCI-H460 (pulmonary) ( 14 , 27 , 45 ) , NCI-H520 (squamous) ( 27 ) , NCI-H524 (pulmonary) ( 12 ) , NCI-H526 (pulmonary) ( 13 ) , NCI-H647 (pulmonary) ( 27 ) , NCI-H661 (pulmonary) ( 17 ) , NCI-H69 (pulmonary) ( 13 ) , NCI-H82 (pulmonary) ( 13 ) , NCI-H838 (pulmonary) ( 18 ) , NPC (neural crest) ( 26 ) , ovary ( 9 ) , PC9 (pulmonary) ( 7 , 27 ) , PC9-IR (pulmonary) ( 7 ) , WM239A (epidermal) ( 6 )

Upstream Regulation
Treatments:
BI2536 ( 34 ) , dasatinib ( 42 ) , MLN8054 ( 34 ) , nocodazole ( 41 ) , SII_angiotensin_2 ( 35 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

6

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

7

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

8

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

9

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

10

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

11

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

16

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

17

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

18

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

19

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

20

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

21

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

22

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

23

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

24

Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

25

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

26

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

27

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

28

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

29

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

30

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

31

Guo A (2011) CST Curation Set: 12065; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

32

Guo A (2011) CST Curation Set: 12066; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

33

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

34

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

35

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

36

Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32
20393185   Curated Info

37

Possemato A (2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

38

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

39

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

40

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

41

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

42

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

43

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

44

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

45

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

46

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

47

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

48

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

49

Stokes M (2008) CST Curation Set: 4609; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

50

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Stokes M (2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

52

Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

53

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

54

Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

55

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info

56

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info